Literature DB >> 7979468

Erythromycin in neonatal postoperative intestinal dysmotility.

D E Simkiss1, I P Adams, U Myrdal, I W Booth.   

Abstract

The motilin agonist erythromycin was used successfully in four infants receiving prolonged parenteral nutrition for severe intestinal dysmotility after gastrointestinal surgery. In a further child with a neuropathic intestinal pseudo-obstruction erythromycin induced a striking small intestinal manometric response, but was without effect in a child with an intestinal myopathy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979468      PMCID: PMC1061099          DOI: 10.1136/fn.71.2.f128

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  6 in total

1.  Erythromycin is a motilin receptor agonist.

Authors:  T Peeters; G Matthijs; I Depoortere; T Cachet; J Hoogmartens; G Vantrappen
Journal:  Am J Physiol       Date:  1989-09

2.  Gastrointestinal motor effects of erythromycin.

Authors:  M F Otterson; S K Sarna
Journal:  Am J Physiol       Date:  1990-09

3.  Relationship of motility to flow of contents in the human small intestine.

Authors:  P Kerlin; A Zinsmeister; S Phillips
Journal:  Gastroenterology       Date:  1982-04       Impact factor: 22.682

4.  Persistent gastrointestinal symptoms after correction of malrotation.

Authors:  S P Devane; R Coombes; V V Smith; W M Bisset; I W Booth; B D Lake; P J Milla
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

5.  Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog.

Authors:  Z Itoh; M Nakaya; T Suzuki; H Arai; K Wakabayashi
Journal:  Am J Physiol       Date:  1984-12

6.  Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies.

Authors:  J Janssens; T L Peeters; G Vantrappen; J Tack; J L Urbain; M De Roo; E Muls; R Bouillon
Journal:  N Engl J Med       Date:  1990-04-12       Impact factor: 91.245

  6 in total
  8 in total

1.  Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants.

Authors:  P C Ng; K W So; K S Fung; C H Lee; T F Fok; E Wong; W Wong; K L Cheung; A F Cheng
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

2.  Cisapride reduces neonatal postoperative ileus: randomised placebo controlled trial.

Authors:  A Lander; R Redkar; G Nicholls; A Lawson; S R Choudhury; J J Corkery; P Gornall; R G Buick; I W Booth
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-09       Impact factor: 5.747

Review 3.  The association of erythromycin and infantile hypertrophic pyloric stenosis: causal or coincidental?

Authors:  Manfred Hauben; Guy W Amsden
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

4.  Influence of erythromycin on establishment of feeding in preterm infants: observations from a randomised controlled trial.

Authors:  B J Stenson; L Middlemist; A J Lyon
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-11       Impact factor: 5.747

Review 5.  Erythromycin as a prokinetic agent in preterm neonates: a systematic review.

Authors:  S Patole; S Rao; D Doherty
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-05-17       Impact factor: 5.747

6.  Erythromycin establishes early oral feeding in neonates operated for congenital intestinal atresias.

Authors:  Asma Razzaq; C Aqeel Safdar; Salman Ali
Journal:  Pediatr Surg Int       Date:  2009-03-17       Impact factor: 1.827

7.  Nutritional care and candidates for small bowel transplantation.

Authors:  S V Beath; I W Booth; M S Murphy; J A Buckels; A D Mayer; P J McKiernan; D A Kelly
Journal:  Arch Dis Child       Date:  1995-10       Impact factor: 3.791

8.  Influence of high-dose oral erythromycin on feeding intolerance in preterm neonates: A randomized controlled trial.

Authors:  Maryam Saboute; Ali Mazouri; Fatemeh NaimiDehnavi; Nasrin Khalesi; Zahra Farahani
Journal:  Med J Islam Repub Iran       Date:  2018-02-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.